Ran Xiao has more than 20 years of experience in corporate accounting, finance, and business operations in the biotech industry.
Prior to joining Septerna, Ran was the VP of Finance and Corporate Controller at Ambys Medicines, Inc, where she supported the company launch and managed various general and administrative functions through a rapid growth period. Before joining Ambys, Ran served as the Corporate Controller at Corvus Pharmaceuticals, where she played a key role in the company’s initial public offering. Prior to Corvus Ran served as Senior Director of Finance at Intermune, Inc., and was part of the team responsible for accounting operations, financial planning, system implementation and business acquisition. Prior to Intermune, Ran held various managerial positions at Natus Medical, Celera Genomics and CV Therapeutics.
Ran received her BS in accounting from Shanghai University of Finance and Economics and her MBA from the Illinois Institute of Technology. Ran holds the Chartered Financial Analyst designation from the CFA Institute.